Neutrophil differentiation

Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026

Same author

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Blood advances·2026

Same author

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

The Journal of molecular diagnostics : JMD·2025

Same author

A clinical guide to TP53 mutations in myeloid neoplasms.

Blood·2025

Same author

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

Nature genetics·2025

Same author

How chemotherapy shapes hematopoietic stem cells.

Nature genetics·2025

Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026

Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026

Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026

Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026

Related Experiment Videos

Neutrophil differentiation

Related Concept Videos

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

A clinical guide to TP53 mutations in myeloid neoplasms.

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

How chemotherapy shapes hematopoietic stem cells.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Related Experiment Videos

Neutrophil differentiation

Related Concept Videos

Related Articles

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

A clinical guide to TP53 mutations in myeloid neoplasms.

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

How chemotherapy shapes hematopoietic stem cells.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.